{"id":"0acccd5f-bc2e-55c2-a91f-a2994dbb750b","stable_key":"252872b9-233f-5692-b72b-c8930ba0cfb7:sil-two-points-on-one-pathway","predicate":"increases","statement":"Sildenafil alone can cause mean peak reductions in systolic and diastolic blood pressure of 10 and 7 millimetres of mercury that are not dose related while heart rate is unchanged, and sildenafil and nitrates both increase cyclic GMP levels in the systemic circulation but at different points along the nitric oxide to cyclic GMP pathway, so the combination is contraindicated because they synergistically potentiate vasodilation; retrospective analysis of concomitant antihypertensive medications did not indicate an increase in adverse events, and concurrent renal or hepatic impairment or CYP3A4 inhibitors could increase systemic exposure.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"0893b83f-c58f-5220-a8f2-8cabbdbddef8","mechanism_event_label":"Both act on the same pathway at different points, which is why together they multiply rather than add.","subject":{"id":"fe62cf8d-5f89-5e19-bc36-03ad3c9063b7","slug":"sildenafil","display_name":"Sildenafil","entity_type_key":"drug"},"object":{"id":"6d2f509b-3a5b-5a38-b3e7-b148581edec9","slug":"cgmp","display_name":"Cyclic guanosine monophosphate","entity_type_key":"small_molecule"},"evidence_count":1,"mechanism_event":{"id":"0893b83f-c58f-5220-a8f2-8cabbdbddef8","stable_key":"252872b9-233f-5692-b72b-c8930ba0cfb7:sil-two-points-on-one-pathway-event","event_type":"observed_intervention","label":"Both act on the same pathway at different points, which is why together they multiply rather than add.","description":"Sildenafil alone can cause mean peak reductions in systolic and diastolic blood pressure of 10 and 7 millimetres of mercury that are not dose related while heart rate is unchanged, and sildenafil and nitrates both increase cyclic GMP levels in the systemic circulation but at different points along the nitric oxide to cyclic GMP pathway, so the combination is contraindicated because they synergistically potentiate vasodilation; retrospective analysis of concomitant antihypertensive medications did not indicate an increase in adverse events, and concurrent renal or hepatic impairment or CYP3A4 inhibitors could increase systemic exposure.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"c654de33-e457-5ca0-8ee6-9f85cdb01c52","slug":"no-cgmp-pathway","display_name":"The nitric oxide to soluble guanylate cyclase to cyclic GMP pathway","entity_type_key":"cellular_process"},"role":"shared_pathway","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"9ec2c9b8-c1c2-53e5-8e72-6a88638b814e","slug":"nitrate-ion","display_name":"Nitrate ion","entity_type_key":"ion"},"role":"interacting_class","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"736a4c55-284d-5361-bf7a-459544e16af1","slug":"systemic-blood-pressure","display_name":"Systemic arterial blood pressure","entity_type_key":"cellular_process"},"role":"measured_endpoint","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"54e95ff1-4ffa-5e6f-a4cb-b47e5d2a5bda","slug":"cyp3a4","display_name":"Human cytochrome P450 3A4","entity_type_key":"protein"},"role":"exposure_determinant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"fe62cf8d-5f89-5e19-bc36-03ad3c9063b7","slug":"sildenafil","display_name":"Sildenafil","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"6d2f509b-3a5b-5a38-b3e7-b148581edec9","slug":"cgmp","display_name":"Cyclic guanosine monophosphate","entity_type_key":"small_molecule"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/sildenafil-research/10078541.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"e65228d2afaad9ce38dccf42c7279ec6b562746aa27b121bf5e5782f36cbe593\", \"start_char\": 0, \"end_char\": 2772, \"text_sha256\": \"e65228d2afaad9ce38dccf42c7279ec6b562746aa27b121bf5e5782f36cbe593\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Review of the cardiovascular profile from the clinical development programme and post-marketing surveillance","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Sildenafil alone and with antihypertensive classes, across clinical trials and spontaneous reports","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A manufacturer-authored review of the development programme rather than an independent analysis, and the post-marketing comparisons are retrospective.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Sildenafil research collection; topical membership is not evidence of a direct clinical effect, and the drug is recorded separately from its N-desmethyl metabolite and its target enzyme from the homologous retinal PDE6.","comparator":null,"unit":null,"notes":"","entity":{"slug":"sildenafil","display_name":"Sildenafil","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Both act on the same pathway at different points, which is why together they multiply rather than add.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[sil-p10078541] Overall cardiovascular profile of sildenafil citrate. (1999). https://pubmed.ncbi.nlm.nih.gov/10078541/ DOI: 10.1016/s0002-9149(99)00046-6","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Cardiovascular system","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"54cabe57-f3a0-590e-8821-ffd3a361520c","evidence_kind":"source_excerpt","locator":"Lines 431-442","start_line":431,"end_line":442,"excerpt":"### sil-two-points-on-one-pathway\nSildenafil alone can cause mean peak reductions in systolic and diastolic blood pressure of 10 and 7 millimetres of mercury that are not dose related while heart rate is unchanged, and sildenafil and nitrates both increase cyclic GMP levels in the systemic circulation but at different points along the nitric oxide to cyclic GMP pathway, so the combination is contraindicated because they synergistically potentiate vasodilation; retrospective analysis of concomitant antihypertensive medications did not indicate an increase in adverse events, and concurrent renal or hepatic impairment or CYP3A4 inhibitors could increase systemic exposure.\nCondition category: biomarker_context\nnutrient_topic: Sildenafil research collection; topical membership is not evidence of a direct clinical effect, and the drug is recorded separately from its N-desmethyl metabolite and its target enzyme from the homologous retinal PDE6.\nplain_language: Both act on the same pathway at different points, which is why together they multiply rather than add.\norganism: Human\ntissue_or_cell_type: Cardiovascular system\nexperimental_model: Review of the cardiovascular profile from the clinical development programme and post-marketing surveillance\nlimitations: A manufacturer-authored review of the development programme rather than an independent analysis, and the post-marketing comparisons are retrospective.\nexposure: Sildenafil alone and with antihypertensive classes, across clinical trials and spontaneous reports\nevidence_span: {\"source_cache\": \"artifacts/sildenafil-research/10078541.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"e65228d2afaad9ce38dccf42c7279ec6b562746aa27b121bf5e5782f36cbe593\", \"start_char\": 0, \"end_char\": 2772, \"text_sha256\": \"e65228d2afaad9ce38dccf42c7279ec6b562746aa27b121bf5e5782f36cbe593\"}\n[sil-p10078541] Overall cardiovascular profile of sildenafil citrate. (1999). https://pubmed.ncbi.nlm.nih.gov/10078541/ DOI: 10.1016/s0002-9149(99)00046-6","model_system":"Review of the cardiovascular profile from the clinical development programme and post-marketing surveillance","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [sil-p10078541] Overall cardiovascular profile of sildenafil citrate. (1999). https://pubmed.ncbi.nlm.nih.gov/10078541/ DOI: 10.1016/s0002-9149(99)00046-6","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"c6c2a590-1f8f-5fac-b2c7-3aae0440b9fd","stable_key":"import-252872b9-233f-5692-b72b-c8930ba0cfb7","title":"Sildenafil: the enzyme it occupies instead of the substrate, why it cannot start a signal it can only preserve, the organic nitrate interaction that follows from that, the homologous retinal enzyme ten-fold away, and the pulmonary circulation where the same mechanism became a second indication (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"bc81793d20d20d2eaad9cb530b70695d8d8778a3d7136e24715ac3369b939953","revision_id":"301732e1-2446-5b67-b3bd-580164b85b05","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}